Q4 2017 13F Holders as of 12/31/2017
-
Type / Class
-
Equity / Common Stock, $0.01 par value per share
-
Shares outstanding
-
210M
-
Number of holders
-
110
-
Total 13F shares, excl. options
-
90.3M
-
Shares change
-
+6.36M
-
Total reported value, excl. options
-
$443M
-
Value change
-
+$31.9M
-
Put/Call ratio
-
0.46
-
Number of buys
-
58
-
Number of sells
-
-45
-
Price
-
$4.91
Significant Holders of BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share (BCRX) as of Q4 2017
145 filings reported holding BCRX - BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share as of Q4 2017.
BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share (BCRX) has 110 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 90.3M shares
of 210M outstanding shares and own 43.06% of the company stock.
Largest 10 shareholders include BAKER BROS. ADVISORS LP (14M shares), BlackRock Inc. (7.61M shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (7.21M shares), RA CAPITAL MANAGEMENT, LLC (6.98M shares), JANUS HENDERSON GROUP PLC (6.74M shares), Vanguard Group Inc (5.78M shares), GREAT POINT PARTNERS LLC (4.75M shares), STATE STREET CORP (3.89M shares), MILLENNIUM MANAGEMENT LLC (3.71M shares), and RTW INVESTMENTS, LP (3.37M shares).
This table shows the top 110 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.